National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach_Chinese Journal of Ocular Fundus Diseases

Authors：

 Fundus Fundus Disease Group of Ophthalmological Society of Chinese Medical Association ,  Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association

Corresponding author：

Fundus Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Email: drxuxun@sjtu.edu.cn; Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, Email: dr_lixiaoxin@163.com

Keywords：

Chronic disease management; Fundus disease; Expert consensus; Modified Delphi approach

DOI：

10.3760/cma.j.cn511434-20240220-00076

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The population of various fundus diseases in China is vast, and the number of patients is continuously increasing due to the aging population. In contrast, fundus disease awareness among the general public in China is low, and grassroots screening needs urgent improvement. At the same time, the diagnosis and treatment rate are quite low, and the treatment methods for late-stage diseases are limited, resulting in poor prognosis of visual function and high blindness rate. Chronic fundus diseases require long-term, standardized treatment and long-term follow-up, which can be burdensome for patients, leading to high missed visit rates and reduced therapeutic effects. The "14th Five-Year Plan for Eye Health (2021-2025)" clearly put forward the requirements of strengthening the construction of the fundus disease prevention and control system. We urgently need to develop a management model for chronic diseases of fundus diseases tailored to China's national conditions. This will require establishing corresponding management platforms, improving personnel allocation, and enhancing compliance in the treatment of fundus diseases, to improve treatment effectiveness and fundamentally reduce blindness rates. After China's authoritative experts in the field of fundus diseases through the organization of in-depth and comprehensive thematic discussion, and the use of the improved version of Delphi method for collective decision-making and opinion consultation, a series of consensus guidance and suggestions were finally formed. These valuable professional insights will strongly promote the establishment of an appropriate chronic fundus disease management system in China, ensure that patients with fundus disease get long-term, standardized medical services, and lay a solid foundation for improving the overall prevention and treatment of fundus diseases.

Citation： Fundus Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach. Chinese Journal of Ocular Fundus Diseases, 2024, 40(4): 253-263. doi: 10.3760/cma.j.cn511434-20240220-00076 Copy

1.	国家卫生健康委. “十四五”全国眼健康规划(2021-2025年)[EB/OL]. [2022-01-04]. http://www.nhc.gov.cn/yzygj/s7653/202201/d607d24b6b1c4bd9b827eedf41eff820.shtml.National Health Commission. 14th Five-Year Plan for Eye Health (2021-2025)[EB/OL]. [2022-01-04]. http://www.nhc.gov.cn/yzygj/s7653/202201/d607d24b6b1c4bd9b827eedf41eff820.shtml.
2.	Song P, Du Y, Chan KY, et al. The national and subnational prevalence and burden of age-related macular degeneration in China[J/OL]. J Glob Health, 2017, 7(2): 20703[2017-12-01]. https://pubmed.ncbi.nlm.nih.gov/29302323/. DOI: 10.7189/jogh.07.020703.
3.	Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J/OL]. Lancet Glob Health, 2014, 2(2): e106-e116[2014-01-03]. https://pubmed.ncbi.nlm.nih.gov/25104651/. DOI: 10.1016/S2214-109X(13)70145-1.
4.	Ye H, Zhang Q, Liu X, et al. Prevalence of age-related macular degeneration in an elderly urban chinese population in China: the Jiangning eye study[J]. Invest Ophthalmol Vis Sci, 2014, 55(10): 6374-6380. DOI: 10.1167/iovs.14-14899.
5.	Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis[J]. Ophthalmology, 2021, 128(11): 1580-1591. DOI: 10.1016/j.ophtha.2021.04.027.
6.	Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
7.	Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036-1042. DOI: 10.1016/j.ophtha.2016.01.006.
8.	Baird PN, Saw SM, Lanca C, et al. Myopia[J]. Nat Rev Dis Primers, 2020, 6(1): 99. DOI: 10.1038/s41572-020-00231-4.
9.	Scott IU, Campochiaro PA, Newman NJ, et al. Retinal vascular occlusions[J]. Lancet, 2020, 396(10266): 1927-1940. DOI: 10.1016/S0140-6736(20)31559-2.
10.	Lau JT, Lee V, Fan D, et al. Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population[J]. Br J Ophthalmol, 2002, 86(10): 1080-1084. DOI: 10.1136/bjo.86.10.1080.
11.	Zhang CX, Zhang GM, Ma N, et al. Awareness of age-related macular degeneration and its risk factors among Beijing residents in China[J]. Chin Med J (Engl), 2017, 130(2): 155-159. DOI: 10.4103/0366-6999.197994.
12.	周芬, 谢红莉, 瞿佳. 眼科资源现状及服务能力调查[J]. 中国医院, 2008, 12(4): 14-16. DOI: 10.3969/j.issn.1671-0592.2008.04.006.Zhou F, Xie HL, Qu J. Investigation on ophthalmology resource and service skill[J]. Chinese Hospitals, 2008, 12(4): 14-16. DOI: 10.3969/j.issn.1671-0592.2008.04.006.
13.	Polack S, Yorston D, López-Ramos A, et al. Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico[J]. Ophthalmology, 2012, 119(5): 1033-1040. DOI: 10.1016/j.ophtha.2011.11.002.
14.	邹海东, 张晳, 许迅, 等. 上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J]. 中华眼科杂志, 2005, 41(1): 15-19. DOI: 10.3760/j:issn:0412-4081.2005.01.005.Zou HD, Zhang X, Xu X, et al. Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai[J]. Chin J Ophthalmol, 2005, 41(1): 15-19. DOI: 10.3760/j:issn:0412-4081.2005.01.005.
15.	Gonder JR, Walker VM, Barbeau M, et al. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY)[J/OL]. J Ophthalmol, 2014, 2014: 939315[2014-03-26]. https://pubmed.ncbi.nlm.nih.gov/24795818/. DOI: 10.1155/2014/939315.
16.	单侯乾, 潘蓓, 左丽倩, 等. 兰州市糖尿病视网膜病变患者住院费用分析[J]. 中国初级卫生保健, 2019, 33(7): 51-54. DOI: 10.3969/j.issn.1001-568X.2019.07.0017.Shan HQ, Pan B, Zou LQ, et al. Analysis on the hospitalization expenses of patients with diabetic retinopathy in Lanzhou[J]. Chinese Primary Health Care, 2019, 33(7): 51-54. DOI: 10.3969/j.issn.1001-568X.2019.07.0017.
17.	Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression[J]. JAMA Ophthalmol, 2016, 134(9): 1007-1014. DOI: 10.1001/jamaophthalmol.2016.2213.
18.	陈有信. 对年龄相关性黄斑变性的公众认知度亟待提高[J]. 中华眼科杂志, 2009, 45(5): 389-392. DOI: 10.3760/cma.j.issn.0412-4081.2009.05.002.Chen YX. Urgent action needed to raise public awareness of age-related macular degeneration in China[J]. Chin J Ophthalmol, 2009, 45(5): 389-392. DOI: 10.3760/cma.j.issn.0412-4081.2009.05.002.
19.	Meads C, Hyde C. What is the cost of blindness?[J]. Br J Ophthalmol, 2003, 87(10): 1201-1204. DOI: 10.1136/bjo.87.10.1201.
20.	Holz FG, Minnella AM, Tuli R, et al. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: real-world outcomes from the LUMINOUS study[J/OL]. PLoS One, 2020, 15(12): e0244183[2020-12-30]. https://pubmed.ncbi.nlm.nih.gov/33378369/. DOI: 10.1371/journal.pone.0244183.
21.	García Layana A, Adán A, Ascaso FJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach[J]. Eur J Ophthalmol, 2020, 30(5): 1042-1052. DOI: 10.1177/1120672 119861623.
22.	Kodjikian L, Baillif S, Couturier A, et al. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study[J]. Eur J Ophthalmol, 2022, 32(5): 2845-2856. DOI: 10.1177/11206721 211052852.
23.	Özen S, Sag E, Ben-Chetrit E, et al. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach[J]. Rheumatology (Oxford), 2021, 60(8): 3799-3808. DOI: 10.1093/rheumatology/keaa863.
24.	陶洋旭, 李建军. 医疗共识制订方法: 德尔菲法和名义小组法[J]. 国际眼科纵览, 2021, 45(5): 369-373. DOI: 10.3760/cma.j.issn.1673-5803.2021.05.001.Tao YX, Li JJ. Delphi method and nominal group method for medical consensus formation[J]. Int Rev Ophthalmol, 2021, 45(5): 369-373. DOI: 10.3760/cma.j.issn.1673-5803.2021.05.001.
25.	Wagner EH. Organizing care for patients with chronic illness revisited[J]. Milbank Q, 2019, 97(3): 659-664. DOI: 10.1111/1468-0009.12416.
26.	曾志童, 王朝昕, 王慧, 等. 基于国内外最新指南的慢性病个体化、精细化健康管理服务分析及我国发展前景——以糖尿病为例[J]. 中国全科医学, 2021, 24(9): 1037-1044. DOI: 10.12114/j.issn.1007-9572.2021.00.158.Zeng ZT, Wang ZX, Wang H, et al. Individualized and precision health management for diabetes: evidence from the latest guidelines and development prospects in China[J]. Chinese General Practice, 2021, 24(9): 1037-1044. DOI: 10.12114/j.issn.1007-9572.2021.00.158.
27.	薛金玉, 蒋萍萍, 郑广勇, 等. 健康教育对社区高血压患者生存质量的影响[J]. 中华老年心脑血管病杂志, 2015, 17(10): 1048-1051. DOI: 10.3969/j.issn.1009-0126.2015.10.011.Xue JY, Jiang PP, Zheng GY, et al. Influence of health education on quality of life in community hypertensive patients[J]. Chin J Geriatr Heart Brain Vessel Dis, 2015, 17(10): 1048-1051. DOI: 10.3969/j.issn.1009-0126.2015.10.011.
28.	孙晓红, 刘珂珂, 江华, 等. 慢性病保健模型在糖尿病长期管理中的应用研究[J]. 中国全科医学, 2018, 21(31): 3878-3881. DOI: 10.12114/j.issn.1007-9572.2018.00.043.Sun XH, Liu KK, Jiang H, et al. Chronic care model in long-term management of diabetes[J]. Chinese General Practice, 2018, 21(31): 3878-3881. DOI: 10.12114/j.issn.1007-9572.2018.00.043.
29.	欧阳玲, 李宝琪, 杨辉. 瓦格纳慢性病服务模型在中澳糖尿病管理中的运用[J]. 中国全科医学, 2020, 23(33): 4236-4240. DOI: 10.12114/j.issn.1007-9572.2020.00.443.Ouyang L, Li BQ, Yang H. Applying the wagner chronic care model in diabetes management: Australian experience and implications to China[J]. Chinese General Practice, 2020, 23(33): 4236-4240. DOI: 10.12114/j.issn.1007-9572.2020.00.443.
30.	Kong JX, Zhu L, Wang HM, et al. Effectiveness of the chronic care model in type 2 diabetes management in a community health service center in China: a group randomized experimental study[J/OL]. J Diabetes Res, 2019, 2019: 6516581[2019-01-03]. https://pubmed.ncbi.nlm.nih.gov/30719455/. DOI: 10.1155/2019/6516581.
31.	Okada M, Wong TY, Mitchell P, et al. Defining nonadherence and nonpersistence to anti-vascularendothelial growth factor therapies in neovascular age-related macular degeneration[J]. JAMA Ophthalmol, 2021, 139(7): 769-776. DOI: 10.1001/jamaophthalmol.2021.1660.
32.	Droege KM, Muether PS, Hermann MM, et al. Adherence to Ranibizumab treatment for neovascular age-related macular degeneration in real life[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(5): 1281-1284. DOI: 10.1007/s00417-012-2177-3.
33.	中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 中国年龄相关性黄斑变性临床诊疗指南(2023年)[J]. 中华眼科杂志, 2023, 59(5): 347-366. DOI: 10.3760/cma.j.cn112142-20221222-00649.Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China (2023)[J]. Chin J Ophthalmol, 2023, 59(5): 347-366. DOI: 10.3760/cma.j.cn112142-20221222-00649.
34.	中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)——基于循证医学修订[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
35.	中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病专业委员会. 中国视网膜静脉阻塞临床诊疗路径专家共识[J]. 中华眼底病杂志, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association, Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association. Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China[J]. Chin J Ocul Fundus Dis, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.
36.	Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern®[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
37.	Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
38.	陈玲玲, 仇永贵, 杨顺舟. 门诊慢病管理的难点与对策探讨[J]. 中国医疗管理科学, 2017, 7(2): 45-48. DOI: 10.3969/j.issn.2095-7432.2017.02.011.Chen LL, Qiu YG, Yang SZ. Dififculties of chronic disease management in outpatient clinic and discussion on countermeasures[J]. Chinese Journal of Medical Management Sciences, 2017, 7(2): 45-48. DOI: 10.3969/j.issn.2095-7432.2017.02.011.
39.	罗小蓉. 构建慢性病远程健康管理模式的探索[J]. 现代医院管理, 2014, 12(4): 44-46. DOI: 10.3969/j.issn.1672-4232.2014.04.013.Luo XR. Exploration of constructing chronic disease remote health management model[J]. Modern Hospital Management, 2014, 12(4): 44-46. DOI: 10.3969/j.issn.1672-4232.2014.04.013.
40.	Sharma A, Harrington RA, McClellan MB, et al. Using digital health technology to better generate evidence and deliver evidence-based care[J]. J Am Coll Cardiol, 2018, 71(23): 2680-2690. DOI: 10.1016/j.jacc.2018.03.523.
41.	蔡素娟, Bakerjian D. 移动医疗在慢性病管理中的应用研究进展[J]. 中华护理教育, 2016, 13(8): 581-586. DOI: 10.3761/j.issn.1672-9234.2016.08.005.Cai SJ, Bakerjian D. Application research progress of mobile health care in chronic disease management[J]. Chin J Nurs Educ, 2016, 13(8): 581-586. DOI: 10.3761/j.issn.1672-9234.2016.08.005.

1. 国家卫生健康委. “十四五”全国眼健康规划(2021-2025年)[EB/OL]. [2022-01-04]. http://www.nhc.gov.cn/yzygj/s7653/202201/d607d24b6b1c4bd9b827eedf41eff820.shtml.National Health Commission. 14th Five-Year Plan for Eye Health (2021-2025)[EB/OL]. [2022-01-04]. http://www.nhc.gov.cn/yzygj/s7653/202201/d607d24b6b1c4bd9b827eedf41eff820.shtml.
2. Song P, Du Y, Chan KY, et al. The national and subnational prevalence and burden of age-related macular degeneration in China[J/OL]. J Glob Health, 2017, 7(2): 20703[2017-12-01]. https://pubmed.ncbi.nlm.nih.gov/29302323/. DOI: 10.7189/jogh.07.020703.
3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J/OL]. Lancet Glob Health, 2014, 2(2): e106-e116[2014-01-03]. https://pubmed.ncbi.nlm.nih.gov/25104651/. DOI: 10.1016/S2214-109X(13)70145-1.
4. Ye H, Zhang Q, Liu X, et al. Prevalence of age-related macular degeneration in an elderly urban chinese population in China: the Jiangning eye study[J]. Invest Ophthalmol Vis Sci, 2014, 55(10): 6374-6380. DOI: 10.1167/iovs.14-14899.
5. Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis[J]. Ophthalmology, 2021, 128(11): 1580-1591. DOI: 10.1016/j.ophtha.2021.04.027.
6. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
7. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036-1042. DOI: 10.1016/j.ophtha.2016.01.006.
8. Baird PN, Saw SM, Lanca C, et al. Myopia[J]. Nat Rev Dis Primers, 2020, 6(1): 99. DOI: 10.1038/s41572-020-00231-4.
9. Scott IU, Campochiaro PA, Newman NJ, et al. Retinal vascular occlusions[J]. Lancet, 2020, 396(10266): 1927-1940. DOI: 10.1016/S0140-6736(20)31559-2.
10. Lau JT, Lee V, Fan D, et al. Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population[J]. Br J Ophthalmol, 2002, 86(10): 1080-1084. DOI: 10.1136/bjo.86.10.1080.
11. Zhang CX, Zhang GM, Ma N, et al. Awareness of age-related macular degeneration and its risk factors among Beijing residents in China[J]. Chin Med J (Engl), 2017, 130(2): 155-159. DOI: 10.4103/0366-6999.197994.
12. 周芬, 谢红莉, 瞿佳. 眼科资源现状及服务能力调查[J]. 中国医院, 2008, 12(4): 14-16. DOI: 10.3969/j.issn.1671-0592.2008.04.006.Zhou F, Xie HL, Qu J. Investigation on ophthalmology resource and service skill[J]. Chinese Hospitals, 2008, 12(4): 14-16. DOI: 10.3969/j.issn.1671-0592.2008.04.006.
13. Polack S, Yorston D, López-Ramos A, et al. Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico[J]. Ophthalmology, 2012, 119(5): 1033-1040. DOI: 10.1016/j.ophtha.2011.11.002.
14. 邹海东, 张晳, 许迅, 等. 上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J]. 中华眼科杂志, 2005, 41(1): 15-19. DOI: 10.3760/j:issn:0412-4081.2005.01.005.Zou HD, Zhang X, Xu X, et al. Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai[J]. Chin J Ophthalmol, 2005, 41(1): 15-19. DOI: 10.3760/j:issn:0412-4081.2005.01.005.
15. Gonder JR, Walker VM, Barbeau M, et al. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY)[J/OL]. J Ophthalmol, 2014, 2014: 939315[2014-03-26]. https://pubmed.ncbi.nlm.nih.gov/24795818/. DOI: 10.1155/2014/939315.
16. 单侯乾, 潘蓓, 左丽倩, 等. 兰州市糖尿病视网膜病变患者住院费用分析[J]. 中国初级卫生保健, 2019, 33(7): 51-54. DOI: 10.3969/j.issn.1001-568X.2019.07.0017.Shan HQ, Pan B, Zou LQ, et al. Analysis on the hospitalization expenses of patients with diabetic retinopathy in Lanzhou[J]. Chinese Primary Health Care, 2019, 33(7): 51-54. DOI: 10.3969/j.issn.1001-568X.2019.07.0017.
17. Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression[J]. JAMA Ophthalmol, 2016, 134(9): 1007-1014. DOI: 10.1001/jamaophthalmol.2016.2213.
18. 陈有信. 对年龄相关性黄斑变性的公众认知度亟待提高[J]. 中华眼科杂志, 2009, 45(5): 389-392. DOI: 10.3760/cma.j.issn.0412-4081.2009.05.002.Chen YX. Urgent action needed to raise public awareness of age-related macular degeneration in China[J]. Chin J Ophthalmol, 2009, 45(5): 389-392. DOI: 10.3760/cma.j.issn.0412-4081.2009.05.002.
19. Meads C, Hyde C. What is the cost of blindness?[J]. Br J Ophthalmol, 2003, 87(10): 1201-1204. DOI: 10.1136/bjo.87.10.1201.
20. Holz FG, Minnella AM, Tuli R, et al. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: real-world outcomes from the LUMINOUS study[J/OL]. PLoS One, 2020, 15(12): e0244183[2020-12-30]. https://pubmed.ncbi.nlm.nih.gov/33378369/. DOI: 10.1371/journal.pone.0244183.
21. García Layana A, Adán A, Ascaso FJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach[J]. Eur J Ophthalmol, 2020, 30(5): 1042-1052. DOI: 10.1177/1120672 119861623.
22. Kodjikian L, Baillif S, Couturier A, et al. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study[J]. Eur J Ophthalmol, 2022, 32(5): 2845-2856. DOI: 10.1177/11206721 211052852.
23. Özen S, Sag E, Ben-Chetrit E, et al. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach[J]. Rheumatology (Oxford), 2021, 60(8): 3799-3808. DOI: 10.1093/rheumatology/keaa863.
24. 陶洋旭, 李建军. 医疗共识制订方法: 德尔菲法和名义小组法[J]. 国际眼科纵览, 2021, 45(5): 369-373. DOI: 10.3760/cma.j.issn.1673-5803.2021.05.001.Tao YX, Li JJ. Delphi method and nominal group method for medical consensus formation[J]. Int Rev Ophthalmol, 2021, 45(5): 369-373. DOI: 10.3760/cma.j.issn.1673-5803.2021.05.001.
25. Wagner EH. Organizing care for patients with chronic illness revisited[J]. Milbank Q, 2019, 97(3): 659-664. DOI: 10.1111/1468-0009.12416.
26. 曾志童, 王朝昕, 王慧, 等. 基于国内外最新指南的慢性病个体化、精细化健康管理服务分析及我国发展前景——以糖尿病为例[J]. 中国全科医学, 2021, 24(9): 1037-1044. DOI: 10.12114/j.issn.1007-9572.2021.00.158.Zeng ZT, Wang ZX, Wang H, et al. Individualized and precision health management for diabetes: evidence from the latest guidelines and development prospects in China[J]. Chinese General Practice, 2021, 24(9): 1037-1044. DOI: 10.12114/j.issn.1007-9572.2021.00.158.
27. 薛金玉, 蒋萍萍, 郑广勇, 等. 健康教育对社区高血压患者生存质量的影响[J]. 中华老年心脑血管病杂志, 2015, 17(10): 1048-1051. DOI: 10.3969/j.issn.1009-0126.2015.10.011.Xue JY, Jiang PP, Zheng GY, et al. Influence of health education on quality of life in community hypertensive patients[J]. Chin J Geriatr Heart Brain Vessel Dis, 2015, 17(10): 1048-1051. DOI: 10.3969/j.issn.1009-0126.2015.10.011.
28. 孙晓红, 刘珂珂, 江华, 等. 慢性病保健模型在糖尿病长期管理中的应用研究[J]. 中国全科医学, 2018, 21(31): 3878-3881. DOI: 10.12114/j.issn.1007-9572.2018.00.043.Sun XH, Liu KK, Jiang H, et al. Chronic care model in long-term management of diabetes[J]. Chinese General Practice, 2018, 21(31): 3878-3881. DOI: 10.12114/j.issn.1007-9572.2018.00.043.
29. 欧阳玲, 李宝琪, 杨辉. 瓦格纳慢性病服务模型在中澳糖尿病管理中的运用[J]. 中国全科医学, 2020, 23(33): 4236-4240. DOI: 10.12114/j.issn.1007-9572.2020.00.443.Ouyang L, Li BQ, Yang H. Applying the wagner chronic care model in diabetes management: Australian experience and implications to China[J]. Chinese General Practice, 2020, 23(33): 4236-4240. DOI: 10.12114/j.issn.1007-9572.2020.00.443.
30. Kong JX, Zhu L, Wang HM, et al. Effectiveness of the chronic care model in type 2 diabetes management in a community health service center in China: a group randomized experimental study[J/OL]. J Diabetes Res, 2019, 2019: 6516581[2019-01-03]. https://pubmed.ncbi.nlm.nih.gov/30719455/. DOI: 10.1155/2019/6516581.
31. Okada M, Wong TY, Mitchell P, et al. Defining nonadherence and nonpersistence to anti-vascularendothelial growth factor therapies in neovascular age-related macular degeneration[J]. JAMA Ophthalmol, 2021, 139(7): 769-776. DOI: 10.1001/jamaophthalmol.2021.1660.
32. Droege KM, Muether PS, Hermann MM, et al. Adherence to Ranibizumab treatment for neovascular age-related macular degeneration in real life[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(5): 1281-1284. DOI: 10.1007/s00417-012-2177-3.
33. 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 中国年龄相关性黄斑变性临床诊疗指南(2023年)[J]. 中华眼科杂志, 2023, 59(5): 347-366. DOI: 10.3760/cma.j.cn112142-20221222-00649.Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China (2023)[J]. Chin J Ophthalmol, 2023, 59(5): 347-366. DOI: 10.3760/cma.j.cn112142-20221222-00649.
34. 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)——基于循证医学修订[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
35. 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病专业委员会. 中国视网膜静脉阻塞临床诊疗路径专家共识[J]. 中华眼底病杂志, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association, Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association. Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China[J]. Chin J Ocul Fundus Dis, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.
36. Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern®[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
37. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
38. 陈玲玲, 仇永贵, 杨顺舟. 门诊慢病管理的难点与对策探讨[J]. 中国医疗管理科学, 2017, 7(2): 45-48. DOI: 10.3969/j.issn.2095-7432.2017.02.011.Chen LL, Qiu YG, Yang SZ. Dififculties of chronic disease management in outpatient clinic and discussion on countermeasures[J]. Chinese Journal of Medical Management Sciences, 2017, 7(2): 45-48. DOI: 10.3969/j.issn.2095-7432.2017.02.011.
39. 罗小蓉. 构建慢性病远程健康管理模式的探索[J]. 现代医院管理, 2014, 12(4): 44-46. DOI: 10.3969/j.issn.1672-4232.2014.04.013.Luo XR. Exploration of constructing chronic disease remote health management model[J]. Modern Hospital Management, 2014, 12(4): 44-46. DOI: 10.3969/j.issn.1672-4232.2014.04.013.
40. Sharma A, Harrington RA, McClellan MB, et al. Using digital health technology to better generate evidence and deliver evidence-based care[J]. J Am Coll Cardiol, 2018, 71(23): 2680-2690. DOI: 10.1016/j.jacc.2018.03.523.
41. 蔡素娟, Bakerjian D. 移动医疗在慢性病管理中的应用研究进展[J]. 中华护理教育, 2016, 13(8): 581-586. DOI: 10.3761/j.issn.1672-9234.2016.08.005.Cai SJ, Bakerjian D. Application research progress of mobile health care in chronic disease management[J]. Chin J Nurs Educ, 2016, 13(8): 581-586. DOI: 10.3761/j.issn.1672-9234.2016.08.005.

Next Article
Key points interpretation of Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China

Chinese Journal of Ocular Fundus Diseases

National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content